Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Deepening our understanding of quality improvement in Europe (DUQUE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Netherlands,Netherlands,Denmark,Germany,Belgium,United States,Spain,United Kingdom,Poland
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2009-11-01
End date: 2013-08-31
Duration (months): 46.0
Total project cost (EUR): 3921310.61
EU funding (EUR): 2996189.0
Participants: 9
Project status: CLOSED

Context Hospitals in European countries apply a wide range of quality improvement strategies; however, knowledge on the effectiveness of these strategies is limited. Objectives We propose to study the effectiveness of quality improvement systems in European hospitals. Specific research objectives are: a) to develop a maturity classification model for the assessment of organizational quality improvement systems in EU hospitals; b) to investigate associations between the maturity of quality improvement systems and measures of organizational culture, professional involvement and patient empowerment (at hospital level); c) to investigate associations between the maturity of quality improvement systems and measures of clinical effectiveness, patient safety and patient involvement (at patient and departmental level); d) to identify factors influencing the uptake of quality improvement activities by hospitals including external pressure as enforced by accreditation, certification or external assessment programmes. Design DUQUE will apply multi-method approaches to data collection, measurement and analysis. Data will be collected at hospital, departmental, professional and patient level. We will employ a multi-level study design in which patient-level data is nested in hospital departments, which are nested in hospitals in different EU countries. Setting We will collect data at hospital and departmental level in the Czech Republic, France, Germany, Poland, Portugal, Spain, Turkey and the United Kingdom in 30 randomly selected hospitals. In each country, for 12 of these 30 hospitals we will carry out additional data collection at the patient-level. Expected outcomes The products of DUQUE will include a catalogue of instruments to build a department and/or hospital specific quality and safety programme and an appraisal scheme to assess the maturity of the quality improvement system.

Keywords: quality improvement systems,european hospitals,quality and safety,patient involvement
Use of a Multidrug Pill In Reducing cv Events (UMPIRE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: United Kingdom,Ireland,Netherlands,India,Australia
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-02-01
End date: 2013-01-31
Duration (months): 36.0
Total project cost (EUR): 4154961.8
EU funding (EUR): 2999866.0
Participants: 8
Project status: CLOSED

Cardiovascular disease is the focus of this proposal as it is the leading cause of mortality worldwide. People with established vascular disease represent a target for secondary prevention using combination therapy that addresses multiple risk factors. Barriers to effective delivery of proven secondary preventative treatments create important gaps in the uptake. These gaps vary in different countries. Complexity and cost of treatment confer particularly difficult barriers; typically an individual recovering from a stroke or heart attack might be advised to take multiple medications to address cholesterol, blood pressure and platelet function. A combination once daily polypill may address these issues. Such a pill, the Red Heart Pill, has been formulated by Dr Reddy’s Laboratories in India. It is remarkably inexpensive with a projected annual cost in India of about €15. Evidence of safety and efficacy of this low-cost fixed-dose, once-daily polypill derived from a carefully conducted clinical trial will support its use in resource-poor countries and internationally. This project aims to evaluate whether provision of a cardiovascular polypill compared with usual medications improves adherence to therapies and clinical outcomes among high-risk patients. Further aims are to measure prescription of combination therapy, barriers to adherence, quality of life, safety, cardiovascular events, and healthcare resource consumption. The results will be used to develop recommendations for equitable access relevant to both Europe and India. India has been chosen as an ICPC partner as it is the home of a large global generic pharmaceutical company – Dr Reddy’s – and about 1 in 4 heart attacks globally occur in India. Parallel polypill projects running in Australia and New Zealand will afford the opportunity of pooling data to assess effects on cardiovascular outcomes. This synergy will enhance the generalisable impact of the UMPIRE trial.

Keywords: polypill,red heart pill,cardiovascular disease,adherence,secondary prevention,equitable access
PRecursors of ExplosiVes: Additives to Inhibit their use including Liquids (PREVAIL)

Framework: FP7 — Cooperation
Programme: Security
Destination: Increasing the Security of citizens
Action type: Collaborative project
Countries involved: Sweden,Netherlands,Israel,France,Norway,France,Poland,Sweden,United Kingdom
Call:  (FP7-SEC-2009-1, 2009)
Start date: 2010-09-01
End date: 2013-10-31
Duration (months): 38.0
Total project cost (EUR): 4296266.87
EU funding (EUR): 3343162.0
Participants: 10
Project status: CLOSED

Homemade explosives (HMEs) are easy to make from readily available materials used for legitimate purposes in everyday life. This availability attracts terrorists to manufacture and use homemade explosives since military and commercial explosives are harder to come by. Two approaches to improve this situation exists. 1) Prohibit or limit the accessibility of these precursor chemicals 2) Use science to solve this problem by making it harder for potential terrorists to make HMEs or by facilitating the detection of these. PREVAIL will address these scientific challenges by a novel approach. The PREVAIL concept and objectives are to prevent the use of hydrogen peroxide (HP) and acetone as precursors to homemade explosives by the development of a series of novel inhibitors, and to ensure that the detection of ammonium nitrate (AN) based devices is facilitated by adding markers tailored to a very sensitive detection system. These objectives must be met without obstructing the legitimate use or causing any adverse effects on the environment or people’s health. The PREVAIL project main activities are development and testing of markers for the inhibition of TATP production and for the concentration of HP by boiling off water (as was done for the London bombings) as well as development of novel markers for easy detection of illicit use of fertilizers. The final outcome of the PREVAIL project are inhibitors for illicit production of TATP and HP based explosives as well as novel marker/detector systems for easy detection of AN based bombs. The PREVAIL project will work together with the chemical manufacturing industry in order to achieve early industrial acceptance of the research. The PREVAIL consortium consists of four research institutes (FOI, TNO,CEA, WIHiE), two chemical industries representing the End Users (Yara, Arkema), three SMEs (Inscentinel, KCEM, SECRAB) and one university (Technion).

Keywords: precursors,home made explosives,explosives,liquid explosives,tatp,hydrogen peroxide,ammonium nitrate,inhibitors,markers,detection
A European gateway to the science and research of health, through online and offline innovative activities aimed at citizens, patients, pupils and teachers (XPLORE HEALTH)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: Spain,Belgium,United Kingdom
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-01-01
End date: 2012-08-31
Duration (months): 32.0
Total project cost (EUR): 842771.19
EU funding (EUR): 779924.06
Participants: 5
Project status: CLOSED

Xplore Health is a joint initiative to build and promote an online and offline interactive environment – with multimedia tools and attending activities – that will nurture active engagement of society with state-of-the-art science and research around health and its wider ethical, legal and social aspects (ELSA) by facilitating an effective dissemination of attractive, accessible and rigorous resources at European level primarily aimed at students and patients’ associations. Effective communication of science and research on health is of special importance as there is a public, e.g. ills as their families, on the one hand, and students, on the other hand, looking for easy-access timely research translated into comprehensive language. Still, it is necessary public discussion, as well as an active informed social debate about ELSA in areas of medical science. The goal of this project is to create a new scientific Portal called “Xplore Health” structured on modules that will be published regularly months, each module covering a different subject. The modules will be presented through a home area where an attractive multimedia presentation will allow the access to the interactive environment which, by the use of Web 2.0 tools, will stimulate direct feedback from users as well as the submission of new contents by qualified scientists and press officers and interested citizens. Expertise in the consortium on public needs and targets will allow efficient surveying to build area specifications adapted to different groups and national sensibilities. As a complement, all during the project attending activities will be organised in schools and museums around Europe in parallel with an intense promotion at European level. Xplore Health has assembled a strong consortium with partners experienced in health research communication, carried out hand by hand with researchers, as well as European networks being communication channels experienced at arranging outreach activities in museums and schools. Additionally, the participation of project management office assures smooth project development.

Keywords: life science dissemination,interactive environment,outreach,multimedia tools,web2.0,european network,patients associations,families,students
COmparative POlice Studies In The Eu (COMPOSITE)

Framework: FP7 — Cooperation
Programme: Security
Destination: Security and society
Action type: Collaborative project
Countries involved: Netherlands,Netherlands,Netherlands,Germany,Germany,United Kingdom,United Kingdom,France,Belgium,Spain,Romania,Czechia,North Macedonia,France,Italy
Call:  (FP7-SEC-2009-1, 2009)
Start date: 2010-08-01
End date: 2014-07-31
Duration (months): 48.0
Total project cost (EUR): 8904352.73
EU funding (EUR): 6623303.0
Participants: 15
Project status: CLOSED

Police forces in the EU face serious challenges. Integration in the EU has increased the need for cross force collaboration. Technology has created new capabilities for criminals but also possibilities for the police. Changes in the public opinion and in political expectations have created extra challenges. Responses to these challenges and exploitation of opportunities require major changes to the culture and structure of police forces, but these are far from trivial and how they need to be implemented differs from one country to another. So far, change management in police organizations has not been addressed in a comparative interdisciplinary study with a European scope. Based on a study of police forces in 10 countries across Europe COMPOSITE will improve the planning and execution of change initiatives in the police, show how these projects can be better aligned with the cultural and societal context per country and explain how the negative process effects can be mitigated. A further aim is to improve both the individual police organization per country and joint European capabilities. The project delivers: 1.A comparative strategic analysis of strengths, weaknesses, opportunities and threats for police organizations in 10 European countries and best practices to meet current and future challenges. 2.A comparative analysis of planning and execution of the change processes, focusing on the impact of leadership, professional and organizational identities and societal expectations. 3.A toolbox containing instruments for training and consultancy and the Annual European Police force monitor to plan and execute changes responding to known and yet unknown challenges and opportunities. The consortium contains universities, business schools, police academies, a technological research institute and consultancy firms. Police forces from the 10 countries are involved in the research and the dissemination phase of the project and they intend to use the results.

Keywords: police in eu,comparative studies,change management,technology adaptation
INtegrated HEart Research In TrANslational genetics of dilated Cardiomyopathies in Europe (INHERITANCE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Italy,United Kingdom,Sweden,Germany,France,United Kingdom,Denmark,Netherlands,Italy,Spain
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-01-01
End date: 2013-12-31
Duration (months): 48.0
Total project cost (EUR): 4028394.24
EU funding (EUR): 2870791.0
Participants: 11
Project status: CLOSED

Inherited dilated cardiomyopathies (DCM) are monogenic disorders caused by mutations in more than 30 genes, characterised by substantial phenotype heterogeneity. DCM affects 1:2.500 individuals and is the major cause of heart transplantation and death for non-ischaemic heart failure in adolescents and young adults. Currently, less than 1% of patients with familial DCM are genotyped in Europe. The INHERITANCE (INtegrated HEart Research In TrANslational genetics of dilated Cardiomyopathies in Europe) consortium propose to investigate over 2,000 existing DCM patients and their relatives in order to translate novel insights on the aetiology and pathophysiology of inherited cardiomyopathies into innovative disease specific diagnostic and treatment strategies. The consortium members share common clinical, scientific and ethical standards with respect to patient care and family screening, and have individual expertise in the clinical management and molecular genetics of inherited cardiomyopathies. The INHERITANCE strategy is to integrate genomic, proteomic, structural and functional studies exploring the molecular cascades arising from causative mutations with innovative clinical assessments in order to understand disease expression, evolution and to explore novel therapeutic strategies both in humans and in animal models. The immediate benefits will include preclinical and presymptomatic diagnosis, family-tailored clinical work-up, optimisation of existing treatment strategies and cost-effective use of medical resources. In the medium term, these studies will catalyse the development of new disease specific protocols, and will provide a model for the exploration of ground-breaking genetic and pharmacological therapies.

Keywords: dilated cardiomyopathy,genetics,pathophysiology,therapies
Promoting sexual- and reproductive health among adolescents in southern and eastern Africa – mobilising parents, schools, and communities (PREPARE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Collaborative project
Countries involved: Norway,South Africa,Uganda,Tanzania, United Republic of,Netherlands,United Kingdom,United Kingdom
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-02-01
End date: 2014-07-31
Duration (months): 54.0
Total project cost (EUR): 3967615.55
EU funding (EUR): 2998017.0
Participants: 9
Project status: CLOSED

The purpose of this project is to develop research-based, culture- and gender-sensitive, sustainable, community-based interventions to promote sexual- and reproductive health among adolescents aged 12-14 years in southern and East Africa, with schools as the gateway for delivery. In two sites (Cape Town and Dar es Salaam), comprehensive, 'best practice', effectiveness studies will be implemented. The aim of the interventions for these studies is that the adolescents use condoms correctly and consistently, postpone sexual debut, or reduce the number of sexual partners. In two other African sites (Limpopo and Kampala), we shall carry out focused efficacy studies. The innovation in the proposal derives from the manner and extent to which we address gender-based violence; parent-child communication on sexuality; culture-specific norms, attitudes and beliefs; active involvement of school students in peer education; contextual factors (physical, organizational and cultural aspects of environments); and 'action planning'. The evaluation includes a process evaluation utilising mainly qualitative methods, and an outcome evaluation involving intervention and comparison groups at all sites. The sample for the effectiveness studies will consist of 15 matched pairs of schools (6000 students), with one school in each pair being randomly allocated to each of the groups in each site. The sample for the efficacy studies will consist of 40 school classes (1200 students) in each group in each site. The theoretical framework draws from social cognition and community mobilisation models. Statistical analyses will exploit current advances in structural equation modelling and multilevel analysis. The use of a biological marker (HSV2) as a proxy for sexual practices will be explored in the first two years of the project. This proposal is perfectly consistent with priorities described under area 4.3.2.1 – Strategies and interventions for improving reproductive health (SICA).

Keywords: aids,health promotion,health education,reproductive health,behavior,intervention,school,community,parents,peers
NEURAL TRANSPLANTATION IN THE TREATMENT OF PATIENTS WITH PARKINSON’S DISEASE (TRANSEURO)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: United Kingdom,Sweden,United Kingdom,United Kingdom,Germany,France,United Kingdom,Austria,United Kingdom,Germany
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-01-01
End date: 2016-06-30
Duration (months): 78.0
Total project cost (EUR): 16142794.19
EU funding (EUR): 11994095.0
Participants: 15
Project status: CLOSED

There are currently no cures for Parkinson&apos;s disease (PD) but one of the most effective reparative therapies in patients to date has been with allotransplants of dopamine (DA) neuroblasts obtained from fetal ventral mesencephalic (VM) tissue. However, this cell transplantation approach has given inconsistent results, with some patients doing extremely well and coming off anti-PD medication for years, whilst others have shown no or only modest clinical improvements, and in some cases also developed severe, off-state graft-induced dyskinesias (GIDs). The reasons behind this heterogeneity of outcomes, and the emergence of GIDs in particular, need to be better understood, not least in the perspective of the rapid advances that are now being made in the development of stem-cell based therapies. There is therefore an urgent need to revisit the trials that have already been done with fetal VM tissue in PD patients, with the expectation that a critical reassessment can form the basis for an optimised and more standardised procedure that will translate into more consistently efficacious transplants with minimal side-effects. Over the last two years a group of international experts, including the key investigators of the previous European and North American trials, has been re-examining the outcome of these trials as well as reviewing the results obtained from recent and ongoing animal experimental studies, and identified a number of weaknesses that may explain the inconsistent outcome in previous trials. As a result of these discussions, the group has agreed to join forces in a new round of experimental work and cell therapy trials in PD, based on a new jointly developed protocol where all these factors are taken into account. In the first instance fetal VM tissue containing mesencephalic DA neuroblasts will be used, with the expectation that this will pave the way for bigger trials using dopaminergic neurons derived from stem cells.

Keywords: parkinson's disease,transplants,dopaminergic cells,patient heterogeneity,graft induced dyskinesias,trial,template,stem cells
Breast Cancer Somatic Genetics Study (BASIS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,Norway,Netherlands,Netherlands,Germany,Netherlands,United States,Belgium,Sweden,France,United Kingdom
Call:  (FP7-HEALTH-2009-two-stage, 2009)
Start date: 2010-07-01
End date: 2014-12-31
Duration (months): 54.0
Total project cost (EUR): 13875833.15
EU funding (EUR): 10499999.0
Participants: 15
Project status: CLOSED

All cancers arise due to somatically acquired mutations in their genomes which alter the function of key cancer genes. Understanding these critical mutational events underlying cancer development is paramount for advancing prevention, early detection, monitoring and treatment of the disease. Breast cancer is the most common class of cancer diagnosed in women worldwide with more than one million cases diagnosed annually. It is responsible for >400,000 deaths per year making it the leading cause of cancer deaths in women and is the most common cause of all deaths in women aged >40yrs. Breast cancer is a heterogeneous disease with a number of subtypes. We propose here to generate complete catalogues of somatic mutations in 500 breast cancers, of the ER+ve HER2- subclass, under the International Cancer Genome Consortium model by high coverage, shotgun genome sequencing of both tumour and normal DNA. All classes of mutations are expected to be detected including base substitutions, insertions, deletions, copy number changes and rearrangements. These catalogues of mutations will afford us statistical power to identify cancer genes that are mutated at a frequency of greater than 3% in this class of breast cancer. Complementary catalogues of epigenomic changes (genome-wide DNA methylation) will be generated for the same cancer samples together with transcript expression profiles. Integrated analyses of these data will be carried out and compared to parallel datasets from other classes of breast cancer and other types of cancer. The potential clinical utility of these findings for detection and monitoring of minimal residual disease will be investigated. Finally, data will be made rapidly available to all scientific researchers with minimal restrictions. The results of this exhaustive and comprehensive set of studies will have an enormous impact on our understanding of the causes and biology of breast cancer and will lead to major advances in detection, prevention and treatment of breast cancer

Keywords: breast cancer,genetics,genome,estrogen receptor positive,her2 negative,sequencing,mutation,rearrangement,expression,methylation,minimum residual disease,translation